Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Renal Impairment
Open-data reference.
33 US clinical trials · 7 currently recruiting
Active & Recent Trials
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
3ive Labs
NCT07017933
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
AstraZeneca
NCT07154901
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
Shionogi
NCT07217886
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
Atea Pharmaceuticals
NCT06911320
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
Pfizer
NCT07315360
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
Eli Lilly and Company
NCT07426380
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
Merck Sharp & Dohme
NCT07348237
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
Eli Lilly and Company
NCT07165015
Effect of Renal Impairment on the Pharmacokinetics of NN9535
Novo Nordisk A/S
NCT00833716
A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function
AbbVie
NCT05940402
Pharmacokinetics of LCQ908 in Patients With Renal Impairment
Novartis Pharmaceuticals
NCT01558323
To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment
Wockhardt
NCT02942810
Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment
Arthrosi Therapeutics
NCT04646889
STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT
Pfizer
NCT04616027
A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment
Amgen
NCT05489614
A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment
Astellas Pharma
NCT00750620
A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function
Exelixis
NCT01761773
Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis
Amgen
NCT01464931
Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects
Novartis Pharmaceuticals
NCT01459250
A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well
Astellas Pharma Global Development
NCT05495581
A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment
Celgene
NCT06318676
Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)
Celgene
NCT01575925
Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function
MBX Biosciences
NCT06496217
Fruquintinib Renal Impairment Study
Hutchmed
NCT05216354
Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment
Genzyme, a Sanofi Company
NCT00445302
Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.
Sanofi
NCT05282030
Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)
Mayo Clinic
NCT01970176
Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex
ContraVir Pharmaceuticals
NCT03284164
A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics
PTC Therapeutics
NCT02286622
A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function
Pfizer
NCT06037031
Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function
Hanmi Pharmaceutical Company Limited
NCT05711381
Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function
National Institute of Allergy and Infectious Diseases (NIAID)
NCT03896750
A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment
Bristol-Myers Squibb
NCT02902679
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 32 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Renal Impairment Trial Landscape
ClinicalTrials.gov lists 33 US studies indexed under Renal Impairment, and 7 of those are currently open to recruitment — roughly 21% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Renal Impairment shows 0 late-stage studies (Phase 3 and Phase 4 combined) alongside 32 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Renal Impairment is led by Pfizer with 3 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 33 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Renal Impairment?
PlainTrial tracks 33 US clinical trials for Renal Impairment, of which 7 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Renal Impairment?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.